<DOC>
	<DOCNO>NCT00234000</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , azacitidine arsenic trioxide , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose azacitidine give together arsenic trioxide see well work treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Azacitidine Arsenic Trioxide Treating Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose azacitidine give combination arsenic trioxide patient myelodysplastic syndrome ( MDS ) . ( Phase I ) - Determine safety tolerability regimen patient . ( Phase I ) - Determine major hematologic response ( erythroid response ) rate patient transfusion-dependent lower-risk MDS treat regimen . ( Phase II ) - Determine complete partial remission rate patient higher-risk MDS treat regimen . ( Phase II ) - Determine toxicity profile regimen patient . ( Phase I ) Secondary - Determine time disease progression patient treat regimen . ( Phase I II ) - Determine overall progression-free survival patient treat regimen . ( Phase I II ) OUTLINE : This multicenter , open-label , phase I , dose escalation study azacitidine follow phase II study . Patients enrol phase II portion stratify accord baseline International Scoring System score ( lower-risk myelodysplastic syndrome [ MDS ] v higher-risk MDS ) . - Phase I : Patients receive azacitidine subcutaneously daily day 1-5 arsenic trioxide IV 1-4 hour day 1 , 4 , 8 , 11 , 15 , 18 , 22 , 25 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients stable disease may receive 8 course therapy . Patients respond disease may continue receive study therapy major response complete remission achieve . Cohorts 3-6 patient receive escalate dos azacitidine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive arsenic trioxide phase I azacitidine phase I one dose level MTD determine phase I . After completion study treatment , patient follow 4 week every 3-12 month survival . PROJECTED ACCRUAL : Approximately 3-18 patient accrued phase I portion study . A total 60 patient ( 30 per stratum ) accrue phase II portion study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Confirmed diagnosis MDS standard criterion . Patients within FAB diagnostic group RA , RARS , RAEB , RAEBt , CMML eligible . For patient lowerrisk MDS : document red blood cell dependence , define inability maintain hematocrit &gt; 25 % without transfusion support . Adequate marrow iron store In patient serum erythropoietin less 200 IU/mL screening , failure respond 2 3 month trial recombinant erythropoietin Serum creatinine serum bilirubin &lt; 1.5 time upper limit normal ; high level acceptable ALT level &lt; 2 x upper limit normal Women childbearing potential must negative serum pregnancy test prior azacitidine/treatment . Women childbearing potential advise avoid become pregnant advise father child receive treatment azacitidine Age &gt; 18 year Treatment growth factor within 30 day first treatment ATO/Azacitidine , except patient serum erythropoietin &lt; 200 IU/mL fail respond trial EPO exclude regardless time since last EPO Treatment cytotoxic experimental agent within 30 day first treatment ATO/Azacitidine Absolute QT interval &gt; 460 msec presence adequate serum potassium magnesium value Active serious infection control antibiotic Pregnant lactate woman Inability unwillingness comply treatment protocol , followup , research test NYHA Class III IV heart failure Poorly control hypertension , diabetes mellitus , serious medical psychiatric illness could potentially interfere completion treatment accord protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>